Abstract
Differentiated thyroid carcinoma (DTC) is rare in children but has a relatively good prognosis. We report 10 pediatric thyroid carcinomas, addressed to our department for additional radioiodine therapy. Lung metastases were detected in all of them by the post therapeutic Iodine131-Whole body scan. Also, all of them under went serum thyroglobulin, chest radiography and / or cervico-thoracic computed tomography (CT). Therapeutic efficacy was observed in the all cases after radioiodine treatment. According to our results, we recommend iodine therapy for remnant ablation or residual disease for most children with DTC and a long-term follow-up because disease can recur decades after initial diagnosis and therapy.
Highlights
Differentiated thyroid carcinoma(DTC) in children is rare as reported by Schlumberger [1]
This present study had the aim to determine prognostic factors that may predict which children with DTC will become free of disease after initial therapy with radioiodine
The findings of the study demonstrated that a large number of children are not free of disease after initial therapy and that clinical factor such as extent of initial disease presentation, especially lymph node metastasis, seemed to be important to predict outcomes after initial therapy in this population
Summary
Differentiated thyroid carcinoma(DTC) in children is rare as reported by Schlumberger [1]. Papillary thyroid carcinoma (PTC) is the most common subtype of DTC in pediatric as well as in adult patients followed by its follicular variant [1,2]. Radiation exposure in infancy has been reported to be associated with the possible occurrence of PTC. Irradiation does not seem to be the only factor favoring its appearance like in our series. Advanced tumor manifestations, such as large or extensive tumor, multicentricity, lymphadenopathy, and synchronous lung metastasis at diagnosis, are more frequent and important risk factors in pediatric patients. Young children have aworse prognosis compared to young adult or adolescent patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
